Role of basic amino acids of the human angiotensin type 1 receptor in the binding of the non-peptide antagonist candesartan

Georges Vauquelin, Frederik L.P. Fierens, Zsuzsanna Gáborik, Tam Le Minh, Jean Paul De Backer, László Hunyady, Patrick M.L. Vanderheyden

Research output: Contribution to journalArticle

12 Citations (Scopus)


To explain the insurmountable/long-lasting binding of biphenyltetrazole-containing AT1-receptor antagonists such as candesartan, to the human angiotensin II type 1-receptor, a model is proposed in which the basic amino acids Lys199 and Arg167 of the receptor interact respectively with the carboxylate and the tetrazole group of the antagonists. To validate this model, we have investigated the impact of substitution of Lys199 by Ala or Gln and of Arg167 by Ala on the binding properties of [3H]candesartan and on competition binding by candesartan, EXP3174, irbesartan, losartan, angiotensin II (Ang II) and [Sar1-Ile8]angiotensin. Our results indicate that both amino acids play an important role in the AT1-receptor ligand binding. Whereas the negative charge of Lys199 is involved in an ionic bond with the end-standing carboxylate group of the peptide ligands, its polarity also contributes to the non-peptide antagonist binding. Substitution of Arg167 by Ala completely abolished [3H]Ang II, as well as [3H] candesartan, binding. Whereas these results are in line with the proposed model, it cannot be excluded that both amino acid residues are important for the structural integrity of the AT1-receptor with respect to its ligand binding properties.

Original languageEnglish
Pages (from-to)S32-S36
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Issue numberSUPPL. 1
Publication statusPublished - Mar 2001


  • Anglotensin II
  • CHO cells
  • Candesartan
  • Human AT-receptor
  • Insurmountable
  • Mutation
  • Non-peptide antagonist

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Fingerprint Dive into the research topics of 'Role of basic amino acids of the human angiotensin type 1 receptor in the binding of the non-peptide antagonist candesartan'. Together they form a unique fingerprint.

  • Cite this